Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABMD Abiomed	$381.02	$380.55	$219.85 ▼ $381.99	$17.18B	1.4	611,028 shs	258 shs
BSX Boston Scientific	$104.30 +0.6%	$103.42	$71.88 ▼ $107.53	$154.34B	0.68	6.66 million shs	2.93 million shs
DXCM DexCom	$82.73 -1.0%	$83.26	$57.52 ▼ $117.19	$32.52B	1.44	4.40 million shs	1.84 million shs
EW Edwards Lifesciences	$76.77 -0.3%	$76.12	$58.93 ▼ $95.25	$45.05B	1.11	5.24 million shs	1.68 million shs
LNTH Lantheus	$79.21 -0.5%	$82.57	$73.11 ▼ $126.89	$5.56B	0.12	1.02 million shs	329,518 shs
MDT Medtronic	$88.50 +0.2%	$85.30	$75.96 ▼ $96.25	$113.36B	0.8	6.99 million shs	2.99 million shs
SYK Stryker	$392.00 +0.0%	$382.92	$314.93 ▼ $406.19	$150.87B	0.91	1.35 million shs	536,295 shs
TMDX TransMedics Group	$128.73 +0.8%	$122.32	$55.00 ▼ $177.37	$4.37B	2.06	1.37 million shs	369,545 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABMD Abiomed	0.00%	0.00%	0.00%	0.00%	0.00%
BSX Boston Scientific	0.00%	-2.37%	+1.84%	+16.17%	+37.03%
DXCM DexCom	0.00%	-4.17%	-3.36%	+38.28%	-25.41%
EW Edwards Lifesciences	0.00%	-1.67%	-1.51%	+10.64%	-15.72%
LNTH Lantheus	0.00%	-2.80%	-0.53%	-12.88%	-0.44%
MDT Medtronic	0.00%	+2.68%	+3.26%	+6.80%	+14.65%
SYK Stryker	0.00%	-0.43%	+2.38%	+13.25%	+18.05%
TMDX TransMedics Group	0.00%	-2.07%	-0.84%	+90.22%	-13.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABMD Abiomed	1.5789 of 5 stars	0.0	0.0	0.0	4.3	0.6	1.7	1.9
BSX Boston Scientific	4.6003 of 5 stars	3.6	3.0	0.0	4.2	2.4	2.5	1.3
DXCM DexCom	4.8961 of 5 stars	3.5	5.0	0.0	4.7	2.8	2.5	1.9
EW Edwards Lifesciences	4.3607 of 5 stars	2.2	3.0	0.0	4.0	2.5	2.5	2.5
LNTH Lantheus	4.4622 of 5 stars	3.5	1.0	0.0	4.2	2.2	2.5	1.9
MDT Medtronic	4.8975 of 5 stars	3.3	3.0	3.3	4.1	3.5	1.7	1.9
SYK Stryker	4.6376 of 5 stars	2.4	3.0	3.3	4.2	3.0	2.5	1.3
TMDX TransMedics Group	1.6277 of 5 stars	1.4	2.0	0.0	0.0	2.4	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABMD Abiomed	0.00	N/A	N/A	N/A
BSX Boston Scientific	3.13	Buy	$116.09	11.31% Upside
DXCM DexCom	2.95	Moderate Buy	$98.50	19.06% Upside
EW Edwards Lifesciences	2.40	Hold	$80.20	4.47% Upside
LNTH Lantheus	3.00	Buy	$130.50	64.75% Upside
MDT Medtronic	2.63	Moderate Buy	$97.87	10.58% Upside
SYK Stryker	2.79	Moderate Buy	$427.30	9.00% Upside
TMDX TransMedics Group	2.80	Moderate Buy	$127.33	-1.08% Downside

Current Analyst Ratings Breakdown

Latest DXCM, ABMD, TMDX, LNTH, SYK, EW, BSX, and MDT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	MDT Medtronic	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Peer Perform
6/23/2025	LNTH Lantheus	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$122.00 ➝ $109.00
6/17/2025	TMDX TransMedics Group	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$130.00 ➝ $150.00
6/17/2025	TMDX TransMedics Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/16/2025	BSX Boston Scientific	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/16/2025	BSX Boston Scientific	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$118.00
6/16/2025	DXCM DexCom	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$102.00
6/16/2025	MDT Medtronic	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/16/2025	MDT Medtronic	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$110.00
6/6/2025	MDT Medtronic	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/4/2025	TMDX TransMedics Group	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$125.00 ➝ $145.00

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABMD Abiomed	$1.03B	16.65	$5.09 per share	74.88	$33.03 per share	11.54
BSX Boston Scientific	$16.75B	9.21	$3.65 per share	28.58	$14.93 per share	6.99
DXCM DexCom	$4.03B	8.04	$2.24 per share	36.90	$5.38 per share	15.38
EW Edwards Lifesciences	$5.44B	8.28	$2.73 per share	28.12	$17.06 per share	4.50
LNTH Lantheus	$1.53B	3.57	$6.99 per share	11.34	$15.65 per share	5.06
MDT Medtronic	$33.54B	3.38	$7.76 per share	11.40	$37.62 per share	2.35
SYK Stryker	$22.60B	6.62	$14.96 per share	26.21	$54.13 per share	7.24
TMDX TransMedics Group	$441.54M	9.86	$1.64 per share	78.52	$6.81 per share	18.90

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABMD Abiomed	$136.51M	$5.82	65.47	69.78	3.33	24.84%	14.77%	13.32%	N/A
BSX Boston Scientific	$1.85B	$1.37	76.13	32.29	2.71	11.58%	18.67%	10.38%	7/23/2025 (Estimated)
DXCM DexCom	$576.20M	$1.34	61.74	33.63	1.77	12.90%	30.05%	10.00%	7/24/2025 (Estimated)
EW Edwards Lifesciences	$4.17B	$7.00	10.97	27.92	3.86	75.48%	16.62%	12.64%	7/23/2025 (Estimated)
LNTH Lantheus	$312.44M	$3.52	22.50	12.55	N/A	16.55%	36.99%	20.55%	7/30/2025 (Estimated)
MDT Medtronic	$4.66B	$3.62	24.45	15.18	2.39	13.90%	14.54%	7.83%	8/19/2025 (Estimated)
SYK Stryker	$2.99B	$7.40	52.97	26.43	2.98	12.31%	23.74%	11.25%	7/29/2025 (Estimated)
TMDX TransMedics Group	$35.46M	$1.36	94.65	90.02	N/A	10.03%	21.88%	6.15%	7/30/2025 (Estimated)

Latest DXCM, ABMD, TMDX, LNTH, SYK, EW, BSX, and MDT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/30/2025	Q2 2025	LNTH Lantheus	$1.65	N/A	N/A	N/A	$389.69 million	N/A
7/30/2025	Q2 2025	TMDX TransMedics Group	$0.48	N/A	N/A	N/A	$146.64 million	N/A
7/29/2025	Q2 2025	SYK Stryker	$3.06	N/A	N/A	N/A	$5.92 billion	N/A
7/24/2025	Q2 2025	DXCM DexCom	$0.45	N/A	N/A	N/A	$1.13 billion	N/A
7/23/2025	Q2 2025	BSX Boston Scientific	$0.72	N/A	N/A	N/A	$4.89 billion	N/A
7/23/2025	Q2 2025	EW Edwards Lifesciences	$0.62	N/A	N/A	N/A	$1.49 billion	N/A
5/21/2025	Q4 2025	MDT Medtronic	$1.58	$1.62	+$0.04	$0.82	$8.81 billion	$8.93 billion
5/8/2025	Q1 2025	TMDX TransMedics Group	$0.29	$0.70	+$0.41	$0.70	$123.39 million	$143.54 million
5/7/2025	Q1 2025	LNTH Lantheus	$1.64	$1.53	-$0.11	$1.02	$377.37 million	$372.76 million
5/1/2025	Q1 2025	DXCM DexCom	$0.33	$0.32	-$0.01	$0.27	$1.02 billion	$1.04 billion
5/1/2025	Q1 2025	SYK Stryker	$2.73	$2.84	+$0.11	$1.69	$5.68 billion	$5.87 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABMD Abiomed	N/A	N/A	N/A	N/A	N/A
BSX Boston Scientific	N/A	N/A	N/A	N/A	N/A
DXCM DexCom	N/A	N/A	N/A	N/A	N/A
EW Edwards Lifesciences	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
MDT Medtronic	$2.84	3.21%	N/A	78.45%	49 Years
SYK Stryker	$3.36	0.86%	N/A	45.41%	32 Years
TMDX TransMedics Group	N/A	N/A	N/A	N/A	N/A

Latest DXCM, ABMD, TMDX, LNTH, SYK, EW, BSX, and MDT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/8/2025	SYK Stryker	quarterly	$0.84	0.88%	6/30/2025	6/30/2025	7/31/2025
5/21/2025	MDT Medtronic	quarterly	$0.71	3.3%	6/27/2025	6/27/2025	7/11/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABMD Abiomed	N/A	7.93	7.17
BSX Boston Scientific	0.47	1.45	0.88
DXCM DexCom	0.55	1.50	1.32
EW Edwards Lifesciences	0.06	4.45	3.66
LNTH Lantheus	0.49	5.74	5.46
MDT Medtronic	0.53	1.85	1.42
SYK Stryker	0.69	1.64	1.00
TMDX TransMedics Group	1.92	9.10	8.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABMD Abiomed	94.48%
BSX Boston Scientific	89.07%
DXCM DexCom	97.75%
EW Edwards Lifesciences	79.46%
LNTH Lantheus	99.06%
MDT Medtronic	82.06%
SYK Stryker	77.09%
TMDX TransMedics Group	99.67%

Insider Ownership

Company	Insider Ownership
ABMD Abiomed	2.50%
BSX Boston Scientific	0.50%
DXCM DexCom	0.32%
EW Edwards Lifesciences	1.29%
LNTH Lantheus	1.50%
MDT Medtronic	0.20%
SYK Stryker	5.90%
TMDX TransMedics Group	7.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABMD Abiomed	2,003	45.09 million	43.96 million	Optionable
BSX Boston Scientific	53,000	1.48 billion	1.47 billion	Optionable
DXCM DexCom	10,300	392.11 million	390.85 million	Optionable
EW Edwards Lifesciences	15,800	586.60 million	579.03 million	Optionable
LNTH Lantheus	700	69.19 million	68.15 million	Optionable
MDT Medtronic	95,000	1.28 billion	1.28 billion	Optionable
SYK Stryker	53,000	381.69 million	359.17 million	Optionable
TMDX TransMedics Group	210	33.82 million	31.46 million	Optionable

DXCM, ABMD, TMDX, LNTH, SYK, EW, BSX, and MDT Headlines

Recent News About These Companies

Analyzing TransMedics Group (NASDAQ:TMDX) and Teleflex (NYSE:TFX)

1 hour ago | americanbankingnews.com

TransMedics Group, Inc. (TMDX) Cash Flow - Yahoo Finance

4 hours ago | finance.yahoo.com

Is TransMedics Stock a Buy After Short-Seller Drama?

July 3 at 8:13 PM | fool.com

TMDX - TransMedics Group Inc Key Metrics - Morningstar

July 3 at 7:15 PM | morningstar.comM

Janney Montgomery Scott LLC Has $592,000 Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)

July 3 at 3:34 AM | marketbeat.com

TransMedics Group, Inc. (NASDAQ:TMDX) Shares Purchased by Peregrine Capital Management LLC

July 2 at 5:25 AM | marketbeat.com

TransMedics Group, Inc. (NASDAQ:TMDX) Shares Purchased by Taylor Frigon Capital Management LLC

June 30, 2025 | marketbeat.com

2 Stocks That Have Doubled This Year and Are Still Worth Buying

June 30, 2025 | fool.com

28,870 Shares in TransMedics Group, Inc. (NASDAQ:TMDX) Acquired by Lisanti Capital Growth LLC

June 29, 2025 | marketbeat.com

Perigon Wealth Management LLC Purchases 4,543 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

June 29, 2025 | marketbeat.com

TMDX - TransMedics Group Inc Sustainability - Morningstar

June 27, 2025 | morningstar.comM

TransMedics Group Inc. (TMDX) Stock Price Today - WSJ

June 26, 2025 | wsj.com

Reasons to Retain TransMedics Stock in Your Portfolio for Now

June 26, 2025 | zacks.com

Global Assets Advisory LLC Invests $1.05 Million in TransMedics Group, Inc. (NASDAQ:TMDX)

June 25, 2025 | marketbeat.com

Oppenheimer & Co. Inc. Has $5.25 Million Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)

June 25, 2025 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX), Solid Biosciences (SLDB) and Novo Nordisk (NVO)

June 24, 2025 | theglobeandmail.com

Oppenheimer Raises TransMedics (TMDX) PT to $150 Following Key OrganOx Metra Label Update

June 24, 2025 | msn.com

TransMedics' Turnaround: The Organ Transplant Leader Is Still A Buy

June 23, 2025 | seekingalpha.com

TransMedics Group, Inc. (NASDAQ:TMDX) Shares Purchased by Cornerstone Wealth Management LLC

June 21, 2025 | marketbeat.com

TransMedics Group, Inc. (NASDAQ:TMDX) Shares Bought by SG Americas Securities LLC

June 19, 2025 | marketbeat.com

Boasting A 18% Return On Equity, Is TransMedics Group, Inc. (NASDAQ:TMDX) A Top Quality Stock?

June 18, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks
By Jeffrey Neal Johnson | June 18, 2025
View Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks
3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
By Jeffrey Neal Johnson | June 18, 2025
View 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated

DXCM, ABMD, TMDX, LNTH, SYK, EW, BSX, and MDT Company Descriptions

Abiomed NASDAQ:ABMD

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.

Boston Scientific NYSE:BSX

$104.30 +0.67 (+0.64%)

Closing price 07/3/2025 03:59 PM Eastern

Extended Trading

$104.30 0.00 (0.00%)

As of 07/3/2025 04:22 PM Eastern

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

DexCom NASDAQ:DXCM

$82.73 -0.85 (-1.02%)

Closing price 07/3/2025 03:57 PM Eastern

Extended Trading

$82.87 +0.14 (+0.17%)

As of 07/3/2025 04:38 PM Eastern

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Edwards Lifesciences NYSE:EW

$76.77 -0.25 (-0.32%)

Closing price 07/3/2025 03:55 PM Eastern

Extended Trading

$76.74 -0.02 (-0.03%)

As of 07/3/2025 04:20 PM Eastern

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Lantheus NASDAQ:LNTH

$79.21 -0.41 (-0.51%)

Closing price 07/3/2025 03:33 PM Eastern

Extended Trading

$79.21 0.00 (0.00%)

As of 07/3/2025 04:45 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Medtronic NYSE:MDT

$88.50 +0.22 (+0.25%)

Closing price 07/3/2025 03:59 PM Eastern

Extended Trading

$88.34 -0.16 (-0.18%)

As of 07/3/2025 05:00 PM Eastern

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Stryker NYSE:SYK

$392.00 +0.19 (+0.05%)

Closing price 07/3/2025 03:57 PM Eastern

Extended Trading

$394.48 +2.47 (+0.63%)

As of 07/3/2025 05:00 PM Eastern

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.

TransMedics Group NASDAQ:TMDX

$128.72 +1.04 (+0.81%)

Closing price 07/3/2025 03:54 PM Eastern

Extended Trading

$127.15 -1.57 (-1.22%)

As of 07/3/2025 04:57 PM Eastern

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DXCM, ABMD, TMDX, LNTH, SYK, EW, BSX, and MDT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DXCM, ABMD, TMDX, LNTH, SYK, EW, BSX, and MDT Earnings

Compare Dividends

Latest DXCM, ABMD, TMDX, LNTH, SYK, EW, BSX, and MDT Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DXCM, ABMD, TMDX, LNTH, SYK, EW, BSX, and MDT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DXCM, ABMD, TMDX, LNTH, SYK, EW, BSX, and MDT Company Descriptions

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools